Cutting-Edge Treatment for Pancreatic Cancer, Bladder Cancer and MoreBioCancell is dedicated to developing cancer treatments suitable for over 40 types of cancer, including pancreatic cancer and bladder cancer. BioCancell's patented, personalized cancer therapy approach is based on the identification of target oncogenes, such as H19. It aims to provide alternative cancer treatments that offer strong therapeutic efficacy combined with a lack of side effects.
The first cancer treatment utilizing H19, designated BC-819, works to destroy cancerous cells only. BC-819 is in advanced clinical trial stages for treatment of pancreatic cancer and bladder cancer. It has also been successfully tested in clinical trials for treatment of ovarian cancer, as well as in compassionate use trials for liver cancer and kidney TCC. Clinical results have shown effectiveness in removing existing cancerous growths and keeping patients clear of new growths.